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The development of tokr-~nce during therapy with orgeoic 
nitrates continues lo be an inptant problem in clinical 
medicine (l-10). Several investigaions have demonstrated 
rapid attenuation of both the hemodynamic and antianginat 
effects of oral, topical and intravenously administered ni- 
Iroles. The mechanism of nitrate tolerance is not complelely 
understwd; however, many investigators have suggested 
that tolerance occurs because of depletion of reduced sulf- 
hydryl groups in vascular smooth muscle (11,W. Although 
there is substantial supportive wideace for the sultIydryl 
dep!.tion hypothesis, there continues to be cwsiderable 
contmversy concerning its clinical relevance (11-16). Re- 
cemly. lhere has hoen increasing interest in the concept that 
ottrate Lherapy is essocialed with both ooumhomural acti- 
vation and plasma volume expansion (10.17-20). Several 
investigaton have prowsed that these responses may play a 
role in loss of nitrole etTects during sustaioed thempy. In 
light of this, efforts have heen made to modify these R- 
s~ooses usinr! both diuretic agents and aneiotensin- 
cbnvening en&no inhibitors (2!-26). 
The purpose of this investigation was to expand previous 
findings concerning the c~~nIerregolatory responses 10 con- 
tinuous nitroglycerin therapy (20) by examining these re- 
sponses duringamote proton&d treatment wkd. A second 
purpose was to examine the impact of angiotenrin- 
converting enzyme inhibitor Ihempy on both the hemody- 
namic and counterregulatory responses to continuous nitro- 
glycerin Ihempy. As thiokontainingangiolensin-converting 
enzyme inhibitors might exert some of thett effects through 
sulfhydryl group donation. we elected fo stu.ly the effects of 
benarepril, a non-thiol-containinp angiotensin-converting 
enzyme inhibitor (25). Previous investigations (2.53) in 
normal volunteers and patients with angina have suggested 
that angiorensin-amverlirtg enzyme inhibitor therapy is ef- 
fective in preventing the loss of airrate effects during SW 
mined Iherapy. In the setting of congestive heart failure 
opposite resulrs have been obtained, with two investigations 
(23,24) revealing that anpiotenrin-Fonvsrting enzyme i&it- 
itor tberatw did not orerent tolerance to the hemodvnamic 
effects o~~ontinuou~ nitroglycerin therapy. No t&l has 
spectfically examined the mechanism by which a non-thiol- 
containing angiotensin-convening enzyme inhibitor might 
modify the development of tolerawe. 
Methods 
Subjects. The s:ody group consisted of 20 normal male 
voltmteen (aged 21 to Sl years, mean 34 + 2) who had no 
history of renal or cardiac disease. All subjects had normal 
findings on physical examination, serum electrolyte, blood 
urea nitrogen, creatininc and hematocrit detemGnations and 
urinalysis. No subject was taking medications at the time of 
the investigation. The study protocol was approved by the 
Committee for the Protection of Human Subjects from 
Research Risks at the Brigham and Women’s Hospital, and 
written infomted consent was obtained in all cases. 
Dutd~hwpilal pbase. Subjects were initially scnened by 
medical history and physical examination. During this visit 
they received a test dose of sublingual nitroglycerin. Each 
subject received 0.4 or 0.6 mg of sublingual nitroglyctin and 
standing blood pressw was monitored over the next 90 mitt. 
Subiects were considered elieible for the trial if they had a 
=I< mm Hg decrease in &ding systolic blood p&sure 
without symptomatic postural hypotension. Two hours &er 
administration of the sublitwal nitroalvcerin dose. a test 
dose of transdermal nilrogly~erin was @plied using a patch 
delivering 0.6 mg/h (14.4 m&74 h) (Transdemt-Nitro, Ciba- 
Geigy Corporation) and standing blood pressure was moni- 
tcred every IS min for the next 90 min. If the subjects did not 
develop sy.nptomatic postural hypotension, they were con- 
sidered eligible for the trial. 
Subjects were randomized to receive benazepril (n = 9) 
or pfacecebo (n = II). Subjects took hettaZepril 10 mg twice a 
day (or matching placebo) for the next 3 days. If they 
tolerated the s’udv medication without side elTects. the dose 
was then incr&ed to 70 mg twice a day (or matching 
placebo). These oral study medications were continued for 
the remainder of the protocol. Of the nine subjects random- 
ized to benazepril, eight received a dose of 20 mg twice aday 
and one received IO mg twice a day. 
Mtospital phase. After 7 to 10 days of outpatient ther- 
apy, subjects were admitted to the Clinical Reskch Center 
at the Brigham and Women’s Hospital for 10davs. Throuahh- 
oat their hospital stay they receivid a diet of known calohc, 
water, sodium, potassium and calcium content. Sodium 
intake was held constant at =200 mEq/day. Subjects were 
given a diet designed to maintein normal caloric intake based 
on their usual dietary intake. 
Study protocol. During the 1st 4 days of hospitalization, 
oral study medications were continued but nitroglycerin was 
not administered. Throughout the horpitalizatior 24-h utile 
collections were made for detemtinatiott of utiw...y so?tum 
output. Subjects were w&bed daily at 8 AM and at 8 PM on 
the same hospital balance scale. Heart rate ned blood 
oressore measuretnents were made at RAM. IO AM. I2 noun 
Hod 4 PM. Heart rata and blood pressure were recorded with 
a Dvnamao (Ctitikon Inc) after the sttbiect had been standint? 
qui&y foF5’min. Three tLsurement; were made separate; 
by I-mitt intervals and the results averaged. 
Llwing the afternoon of day 3, an Ill-gauge heparin lock 
was PI&d in the nondominant forearm of each subject to 
allow venous blood samolina. On hosrhal days 4 through 10 
at g AM and 4 PM, blood’wa;drawtt 1; detem&e hema&& 
level, plasma win activity attd levels of plasma norepitteph- 
rine. atrial natriuretic peptide and arginine vasopressin. 
Blood was drawn after the su’rjeet had been standing quietly 
for IO min. 
Trmsdetmal aitroglyeerin adttd&tnthm. Therapy with 
transdermal nitmglycerin was begun on day 5. Patches were 
applied daily at 8 AM, shortly after morning measurements 
were completed, throughout the remainder of the hospital 
stay. 
SttMhtgttal nltrogly&tt admin&lra!loa. At 4 PM on day 3 
and day IO, all study subjects received sublingual nitroglyc- 
erin. lmmedistely before sttblingaal nitroglycerin admhtis- 
tration, standing heatt rate and blood pressure were deter- 
mined and venous blood samples were drawn for 
mcaswemcnt of plasma renin activity and plasma cate- 
cholamine, atrial natrhretic peptide and ar$.nine vasoprer 
sin levels (time 0). Subjects remained stat&g aad blood 
pressare and heart rate measurements were made at 5, 10 
and 15 ntht after sublingual aitrogJycctin administration. 
Finally, at the 15.min point, venotts blood samples were 
again obtained. Four subjects received a O.+mg dose of 
sublingual nitroglycerin aad 16 received 0.6 mg. 
moae levels were measured using methods that have been 
prcviausly described (20). 
St&stkal tMtods. All data are uresented as the mean 
value f SEM. Data were analyzed dy means of a repeatcd- 
measures analysis of variance, with days, hours and minutes 
as vithin-subject effects, and treatment group (henazcpril 
vs. placebo) as a between-subject &XI. This design yielded 
tests of 1) whether mean values of these measttremcats 
varied significantly across days. 2) whether they exhibited a 
pattern of variation resulting in significant differences across 
hours or minutes, 3) whether the daily effect varied as a 
function of the time at which values were measured. and 4) 
whether the daily, hour or minure effects varied as a function 
of treatment with benazepril YCISUS placebo. In eases where 
significant F values were found, specific preplanned cornpar- 
isons t%tween baseline and subsequent data points were 
petformd. For blood pressure. heart rate, hematocrit and 
hormonal responses to tmnsdemul nitroglycerin, hospital 
day 4 served as baseline for the day etfect and 8 AM served 
as baseline for the hourly effect. For responses to sublingual 
nitroglycerin, hospital day 3 served as baseline for the day 
effect and time 0 (4 PM) served as baseline for the minute 
effects. Differences were considered significant if the null 
hypothesis could be rejected at the 0.05 probability level. 
Results 
Blwd presrw and heart rate responses to tnmsdermal 
ni~mglycerb~ (Fii. I and 2). Standing sj.stolic blood pressure 
at baseline tended to be somewhat lower in the angiotensin- 
converting enzyme inhibitor group than in the placebo- 
treated group. This difference was signilicant at 12 noon but 
not at other measurement points on day 4. the baseline day. 
Similarly, baseline heart rates tended lo he somewhat higher 
in the benazepril-treated group. although this ditkrence only 
achieved stalistical significance at the I2 noon measurement 
point. 
In both groups there was .I significant decrease in stand- 
ing systolic blood pressure on day 5, the initial day of patch 
therapy (p < 0.001. main effect of days in analysis of 
variance). Subsequently, blood pressure in the placebo- 
treated group returned to baseline valuer. Analysis of vari- 
awe reveals rhat there was no significant difference in the 
magitude of this response when the plxeba-treated and 
bmazepril-treated groups were compared. Although there 
appears to be a tendency for systolic blood pressure to 
decrrase after patch reapplication on days 6 and 7 (Fig. I). 
rhls pawn did not represent a statistically reliable finding 
lp > 0.6. et&~t of treatment group on hours by day inter- 
action) 
Tbxe was a sign&ant increase in heart rate in bath 
groups after mltiatian of nitroglycerin therapy that was 
present throuchout days 5 and 6 ID < 0.02. main effect of 
bags in a&is of kiance). &bsequently. heart rate 
returner’ to baseline in bath treatment groups. Analysis of 
variance rrvrals that there was a significant effect of treat- 
ment group on rhe hours by day interaction. This finding 
stems from two occasions on which there were geater 
!ncreases in heart rate after patch application in the phcebo- 
keated pn~p than were seen in the benazepril-treated 
gr”Up. 
I 
5 1 
I 
4 4 ‘ I L 9 
Day in Hospital 
Figwe 5. Twenty-four-hour urine sodium values (mEqi24 h) on the 
day before mitiation of tmnsdermel nitroglycerin CGTN) therapy 
(day 4) end on days 5 to 9 in the plwelwtreated (upper pen@ eed 
benarepril.treated &wer per@ ~ro”ps, Values arc expressed as 
mean value 2 SEM. *p c 0.05, main elect of days in analysis of 
varianc.e. 
Body weight, urinary sodium, end hemateerit responsea 
(Fig. 3 and 4). There was no change in wei@ in either 
treatment group during nitroglycerin therapy. The mean 
weight of the placebc&eated arow at 6 AM on dav 4. the day 
before initiation of transde~al &roSlycerin therapy, &s 
72.6 ? 3.4 kg and at 8 AM on day 10, after 5 days of 
continuous nitroglycerin therapy, it was 72.3 ?: 2.2 k& In the 
benazepril-treated group these values were 79.5 + 2.3 kg and 
79.3 2 2.3 kg, respectively. 
There was no diierence between the placelwreated and 
benazepril-treated groups with respect io 24-h urinary so- 
dium values on day 4, the dav before initiation of transder- 
mal nitroglycerin therapy. S&seqoeotly there was a signif- 
icant decrease in urinary sodium on days 5 and 6, the 1st 2 
days of transdarmal nitroglycerin therapy (Fig. 3: p < 0.003, 
main effect of days in analysis of variance). There was no 
diierence in the urinary sodium responses between the two 
grOUPS. 
In both groups, there was a significant decrease in hemat- 
wit level on day 5 (day I of transdemnl oitroglycerin 
therapy) tbat persisted throughout the treatment period (Pig. 
4). Analysis of variance reveals that there was no significant 
diierence in the magnitude or pattern of hematocrit re- 
spoose. between the plecebo-treated and benazeprit-treated 
groups (p > 0.6, interaction between treatment group and 
day e&t in analysis of variance). There was a significant 
hourly effect throughout the observation period with the 
hematocrit at 8 AM being greater than that seen at 4 PM. This 
hourly eiTect varied significantly across deys. with a si@i- 
rantly kwater decrease in hematwit level occoniog be- 
tween 8 AM and 4 PM on day 5, the 1st day of patch 
application (p i 0.02, interaction of hours by day on day 5). 
This finding indicates that there was a signiJicaot decrease in 
hematocrit level within the 1st 8 h after initial therapy with 
tranrdwmal nitroglycerin. 
Hermenal re+nse# to ti-ansderrml ni(m&cerbl @lg. 5 
and 6). There was no sipi%ant diierence in breline 
values (day 4) of plasma catecholamines, atrial natrioretic 
peptide and argiaioe vasopressin. Plasma ranin activity, as 
F@e 4. Hemeteerit levels (mgldl) ee the day b&n ioitietion of 
trens&m~al nitroglycerin (GTN) tkcrdpy end on days 5 to IO ie the 
placebo-treated (e~pee pld) and benazepril.treetcd (bwer @) 
groups.~numbrrs08andlbonthsxruisindisteS~and4~~, 
respectively. Values are expressed as mean value f SEM. l p < 
0.05. mziin effect of days ia analyak of v&awe. 
expected. was marked!y elevated in the group treated with 
benazepril. There was no significant chaage in plasma nare- 
pinephrine concentration with initiation of transdermal ni- 
troglycerin therapy in the placebo-treated group. Plasma 
norepinephrins concentrations tended to increase after inili- 
ation of tnnsdermal nitroglycerin therapy in the benazepnl- 
treated group (p = 0.059. interaction berween watment 
groupand day effect in analysisof variance: Fig. 5). Plasma 
epinephrine cona n&&ions did not change significantly in 
either group after the initiation of continuous nitroglycenn 
therapy (data not shown). plasma renin activity was not 
aliected by tnnsdemtal nitroglycerin thempy in the placebo- 
treated group. Although there was a tendency for plasma 
renin activity to mcrease after initiation of tnnsdermal 
nitroglycerin therapy in the benazepril-treated group (Fig. 
6), analysis of uriance reveals that this did not achieve 
statistical significance (p > 0.1, interaction between trcilt- 
mnt group and a=y effect). Initiation of tnnsdermal nitro- 
glycerin therapy caused no significant change in atrial naui- 
arctic peptide levels in either therapy group (data not 
shown). Similarly, transdermal nitroglycerin was not asso- 
ciated with a signiticant change in plasma levels of arginine 
vasopressin in either group (data not shown). 
B&d pressure aNd beart rate rrrponrs to snb&r& 
nitroglycerin (Table 1). Administrarion of sublingual nirm- 
glycirin on day 3. the day before transdem~al nirmglycerin 
therapy. cawed a significant decrease in standing systolic 
blood pressure in both the placebo-treated and the 
benazrpril-treated groups along wi;h an increase in standing 
hezz rate. Althaugb the heart rare and blood pr~ssurc 
respooaes to sublingual nitroglycerin were attenuated after6 
days of continuous transdemxd nitroglycerin chempy, this 
difference wab not significant. 
Hummnat respomer to ~ubliag,,al nitmgtycwin (Table 2). 
Administration of sublingual nitroglycerin on day 3. while 
subjr. were in the nitrate-free state. resulted in significant 
inxascs in plasma norepinephrine concentration in both the 
placebc-treated and henazepril-treated group. On day IO, 
after 6 days of continuous transdermat nitmglycerin thenpy, 
there continued to be a signitiicant increase in plasma nor- 
epmephrine :uncentration in response to sublingual nitro- 
glycerin. although the respxse was now significandy less 
thau that been on day 3 (p i 0.05. interaction of days and 
minutes in the analysis of variance: Table 2). Treamtent 
group was found to have a significant elfect on norepineph- 
rine responses to sublingual nitroglycerin: subjects in the 
benazetxil-treated grout had a significantly greater increase 
in plasrk norepinepbrk concentration onbay 3 than that 
seen in the placebo-treated mow CD < 0.02, etTect of 
treatment grokp on interact&of&y; and minutes; Table 
2). Plasma epinsphrine concentration did not change signif- 
icantly in either group in response to sublingual nitroglycerin 
(data not shown). There was a significant increase in plasma 
renin activity in bath treatment groups after administration 
of sublingwl nitroglycerin. Analysis of variance reveals that 
the responses on days 3 and IO were similar but that the 
increase in plasma renin activity was significantly greater in 
the benazepril-treated group than in the placebotreated 
group (p < 0.002. interaction between treatment group and 
effect of minutes in analysis of variance; Table 2). Sublingual 
nitroglycerin administration caused a small reduction in the 
level of atrial natriuretic oeotide (II < 0.04. main effect of 
minutes in analysis of vari&e: T&k 2). Although the effect 
appears to be more pronounced in the benazepril-trented 
group, analysis of variance failed to identify a significant 
effect of treatment group on this response (p > 0.2. interac- 
tion between treatment group and effect of minutes in 
analysis of variance; ‘fable 2). The level of arginine vase- 
pressin increased significantly after administration of sub- 
lingual nitroglycerin in both the placebo-treated and 
benazepril-treated groups. Analysis of vcriance reveals that 
this response was significantly greater on day 3 than on day 
10 (p < O.J2. interaction of days and minuteS in analysis of 
variaw~ Table 2) and that the rerpcmse of the benazepril- 
treated group an day 3 was greater than that seen in the 
placebo-treated group (p < 0.05, effect of treatment group on 
interaction of days and minutes in analysis of variance). 
Diwussion 
Although there is considerable support for the role of 
sulfhydryl group depletion in the development of nitrate 
tolerance (IO-14.16). there IS now increasing evidence that 
other mechanisms may be involved. The first is the phenom- 
Table 1. Hormonal Responses Lo Sublingual Nitroglycerin Administration Before and AfW 
Surtaincd Yhrrara With Tranrdermat Nitmplvcerin 
enon of plasma volume expansion. which has been found 
(17.18,?0.22) to occur rapid!y in response to nitrate admin- 
istration. Second. neurohorrnonal responses have been iden- 
tified that could cause augmented vaaoconstrictive forcer 
and contribute to plasma volume expansion lIU.i7-20.271. 
The relative impor&cs of these mechanisms in the chnrcal 
phenomenon ofnitrate toieraner is not yet known. tt ib clear 
tbat both the nature of these counterregula!ory responses 
and their impact on the development of rutrate tolerance may 
be quite different rn those with normal hemodynamic status 
and in those with congestive heart failure. Nevertheless. the 
recognition of these responses has served to emphasize that 
the development of nitrate tolernnce is a complex and 
multifaceted problem (tg). 
Neurnhomonat rpsponsff to nitroglycerin therapy. The 
present study demonstrates rapid attenuation of the systemic 
herttodynamic responses to transdermal nitroglycerin in both 
the placebotrealed and benazepril-treated groups. The tind- 
ings in the placebo-treated group provide new information 
concerning the relative importance of plasma volume rrpan- 
sion and neurohormonal responses during nitroglycerin ther- 
apy in subjects with normal hemodynamics. We found little 
evidence of neurahormonal activation in response to acute 
and sustained therapy with tnnsdermal nitroglycerin. Thib 
finding stands in sharp contrast to the rewhs presented in a 
recent repot from our own laboratory 1201. in which trrms- 
dertttrtl nitroglycerin administration was associated with 
increases in plasma catecholatnin: levels. plasma renin 
activity and arginine vasopressin levels. The most reason- 
able explanation for these contradictory results is that neu- 
rohonnonal responses are dependent on the dose of nitro- 
glycerin administered. Because the dosage of nitroglycerin 
used in the present investigation (I5 me/24 h, 0.6 r&U was 
approximately B% less than ?ha! used in our previous study. 
there may have been less r&x stimulation of the sympa- 
thetic nervous system and other hormonal control mecha- 
nisms. This concept is supported by the increases in plasma 
norepinephrine concenttntion. plasma renin activity and 
argioine vasopressin level in response to sublingual nitro- 
glycerin a~ninis:ration. Prewnahly, the hemodynamic re- 
sponses to sublingual nitmglycerin provided a more potent 
stimulus than was seen with the dosage of transdetmal 
nitroglycerin used in this study. Finally, in our previous 
study (20). hormone samples were drawn four times a day. 
This higher sampling frequency gave greater power to the 
analysis of variance for detecting horntonal changes in 
response to transdermal nitroglycerht. If the present study 
had used the same sampling frequency. it is possible that 
some of the observed responses (prticularly those in the 
benaaeprd-treated group) would have achieved significance. 
Although the present findings suggest hat neurohortnonal 
responses do not play an important role in the loss of nitrate 
effects. it is not possible to dnw this conclusion with 
certainty. Plasma hormone levels may not provide rhe most 
aefurate methodofdeterrnining sympathetic nervous system 
activity or the activity of other hormonal systems. It is now 
recognized that many tiswe: hwe local hormonal systems 
whosz activity may not be manifested by systemic plasma 
hormone levels (29). For example, plasma catecholamine 
levels may be a poor index of sympathetic nervous system 
act~vny. In this regard. Meredith and colleagues (30) have 
shown that changes in plasma norepinephrine concentra- 
lions reflect not only alterations in neural norepinephrine 
productton. but also changes in the rate of clearance of 
norepmerhnne by the kidney and orher tissues. Thus it is 
powblc that reponed increaes in plasma caircholamine 
levels w rcrpcnse to nitrate administration reflect either 
increased rympaihetic nervous system activity or nitrate- 
rnduced decreases m glomerular filtration rate. or a combi- 
muon of Ihex factors. 
Ptasnta vulurne expansion during nttmglycerirt therapy. In 
conrrxr. Ihi> investigation iprovides strong evidence that 
plasma volume expansion plays 8” important role in the loss 
of hemodywmic effecrs of continuous nitroglycerin therapy. 
Evidence of plasma volume expansion. as manifested by a 
dccriase in hem&writ. developed within 8 II of initiation of 
trnnsdermal nitroglycerin thenpy and persisted throughout 6 
days of cotttmuous therapy. Plasma volume expansion dur- 
ing nirro~tycerm therapy has been a consistent finding in 
~cvcrnl rwesrigntions involving nornml volunteers (17,20), 
patients wth acute myocardird infarction (331) and patients 
with congestive heart Failure (IS). This studv demonstrates 
that plr&a vuhtme expansion is not a t&ient phenome- 
non. as hematocrit levels remained depressed throughout he 
bd.ty treatment period. Although the mechanism of nitrate- 
induced pbasrna volume expansion remains unknown. the 
present studv suooorts the hvoothesis that it occurs second- 
&y to a lr&sv&dsr Auid’shift due to an alteration in 
Startinn forces (18). This theorv holds that a reduction in 
venular hydrostatic pressure induced by nitrates, wirh no 
change in oncotic pressure. would lead to a transmembrane 
shift of Kuid from the extravascular to the inlrwascular 
compartment. Sodium retention may play rotne role in this 
phenomenon: however, in the present investigation sodium 
retention was moderate. manifested only during the 1st 2 
days of transdcrmal nitroglycerin therapy and was not asso- 
ciated with an increase in body weight. Although venous 
blood sampling may have contributed to the observed de- 
crease in hrmatocrit. the majority of the observed change in 
hernatocrit occurred during the 1st 8 h of nitmglycerin 
therapy, in the absence of any intercurrent blood sampling. 
Fsrthennorc. in a previous study we !tave observed a 
persistent decrease in hematoerit afler 5 Lo 7 days oi nitro- 
glycenn therapy, using a study design in which there was no 
venous blood sampling during the sustained nitroglycerin 
treatment period (22). Despite this. it cannot be pmved that 
plasm* volume expansion plays a causative role in the loss of 
hemodynamic effect of sustained nitroglycerin therapy. 
EKect of anglolensin.convtrKng enzyme inhihithut. Our 
dd!a suggest Ihat benazepril, a non-thinl-containing angio- 
tensin-converting enzyme inhibitor, does not modify the 
systenuc ltcmodynamic responses to continuous therapy 
with lrmsdemml nitroglycerin. It has been suggested tbal 
angiotcnsin-convertingenryme inhibitors might beLzneticial 
in preventing nitrate tolerance by decreasing angiotensin II 
production. thus limiting both its direct effects on veno”s 
and arterial tone and its effects on renal handling of sodium 
(25,28). Otlwr proposed beneficial effects of angiotensin- 
convening enzyme inhibitor therapy include decreased se- 
cretion afar&nine vasopressin and prevention ofangiotensin 
II-mediated enhancement of sympathetic outflow (32). The 
present investigation suggests that angiotensin-converting 
enzyme inhibition does not prevent these counterregulatory 
responses to continuous nitroglycerin therapy. In both the 
placebo-treated and benarepril-treated groups there was 
similar evidence of plasma volume expansion. Sodium R- 
tention, which occurred during the 1st 2 days ofnitroglycerin 
therapy, was not significantly reduced in the bemazcpril- 
treated group. Although there can be little doubt that angio- 
tensin-converting enzyme inhibitor therapy decreased the 
systemic and local production of angiotensin II. there was no 
evidence in the present study that this therapy was associ- 
ated with less sympathetic aervous system activation. If 
anything, plasma norepinephrine responses to both transder- 
mal and sublingual niiroglycerin were greater in the group 
receiving benazepril. 
These findings are in agreement with recent reports 
(23.24) demonstrating that captopril was ineffective in pre- 
venting tolerance to the bemodynamic effects of nitrogiyc- 
erin in patients with congestive heart failure. In contrast, 
Katz et al. (251 have reoorted that aneiotenain-convertine 
enzyme inhibitors successfully prevented the developmeni 
of tolerance to transdermal nitroglycerin as assessed by 
changes in forearm venous blood volume in response to 
sublingual nitroglycerin. The end points examined in the 
Katz study were quite different from those used in the 
present investigation, and it is possible that therapy with an 
angiotensin-converting enzyme inhibitor during continuous 
therapy with nitroglycerin is associated with persistent ef- 
fects on venous distensibility that were not detected by the 
systemic hemodynamic measures used in the present study. 
Nevertheless, in a previous study from our laboratory, 
analysis of the systemic hemodyrmmic responses to trans- 
dermal nitroglycerin has been successful in documenting 
both the development of tolerance during sustained nitm- 
glycerin therapy and its prevention during intermittent ther- 
apy (20). Data concerning the imoact of anaiotensin- 
converting enzyme inhibit&therapy dn the development of 
nitrate tolerance in patients with angina remains limited: 
however, one preliminary report suggesrs that therapy with 
a non-thiol-containing angiotensiwconverting enzyme inhib- 
itor successfully prevented the develooment of tolerance as 
defined by treadmill walking performance in patients with 
stable awinn (26). It is not oossible to conclude from the 
present data whether attgiote~sin-converting enzyme inhib- 
itors will have a role in the prevention of nitrate tolerance 
during the treatment of either angina or congestive heart 
failure. Our data suggest that if these agents do have 
beneficial effects in patients not suffering from congestive 
hear? failure, they do not seem to be mediated through thrir 
impact on plasma volume or other counterre~ulatory re- 
sponses. 
A final important finding of this investigation is evidence 
of continued vascular activity of nitroglycerin long after the 
systemic hemodynamic responses to tmnsdermal nitmglyc- 
win have been lost. This is seen most strikingly in the 
decrease in bematocrit that occurred rapidly after the initi- 
ation of nitrate therapy and continued throughout the 6&y 
treatment period. Continued vascular responsiveness to 
nitroglycerin is also seen in the hemadynaiic responses to 
suhlinaual nitroalvcerin. Althouah there is cosolete loss of 
the h&t rate aici blood press& responses to’irzt~dermal 
nitroglycerin, the continued significant hemodynamic re- 
sponses to sublingual nitroglycerin suggests that complete 
tolerance to the vascular effects of nitroglycerin has not 
really occurred. We hypothesize that sublingual oitroglyc- 
erin administration causes increased venodilation (through a 
transient increase in plasma nitroglycerin levels) and ihat 
this explains the continued hemodynamic effect even though 
plasma volume has already increased. 
Corlusknr. This investigation suggests that plasma vol- 
tnne expansion may play an impwtant role in the loss of nitrate 
effects over time. Tbe lack of neurohmmonal responses may 
help to explain why therapy with an angiotensin-converting 
enzyme inhibitor did not modify hemodynanic responses to 
sustained therapy with rransdemtal nitmglycerin. Evidence for 
continued vascular activity of nitr@ycerin during sustained 
nitroglycerin thetapy emphasizes that the clinical phenomenon 
ofnittatetokrancedos not imply complete loss ofthe efkct of 
the organic nitrafes at the vascular smooth muscle ce8 level. 
Further investigation will be requb-ed to determine whether 
counterrgulatory responses can be moditied in such a manner 
as to improve present treatment strategies ttsinp the orgattic 
nitrates. 
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